4//SEC Filing
Hughes-Wilson Alexandra 4
Accession 0000950170-24-064274
CIK 0001719714other
Filed
May 22, 8:00 PM ET
Accepted
May 23, 9:54 PM ET
Size
17.8 KB
Accession
0000950170-24-064274
Insider Transaction Report
Form 4
Hughes-Wilson Alexandra
See Remarks
Transactions
- Exercise/Conversion
American Depositary Shares representing Ordinary Shares
2024-05-22$1.40/sh+93,333$130,666→ 100,983 total - Exercise/Conversion
American Depositary Shares representing Ordinary Shares
2024-05-22$1.01/sh+75,000$75,750→ 82,650 total - Sale
American Depositary Shares representing Ordinary Shares
2024-05-22$2.99/sh−50,350$150,547→ 58,633 total - Tax Payment
American Depositary Shares representing Ordinary Shares
2024-05-22$1.40/sh−42,983$60,176→ 7,650 total - Sale
American Depositary Shares representing Ordinary Shares
2024-05-22$2.94/sh−50,082$147,241→ 32,568 total - Tax Payment
American Depositary Shares representing Ordinary Shares
2024-05-22$1.01/sh−24,918$25,167→ 7,650 total - Exercise/Conversion
Share Options (Right to buy)
2024-05-22$1.01/sh−75,000$75,750→ 0 totalExercise: $1.01Exp: 2033-01-25→ American Depositary Shares (75,000 underlying) - Exercise/Conversion
Share Options (Right to buy)
2024-05-22$1.40/sh−93,333$130,666→ 0 totalExercise: $1.40Exp: 2032-01-14→ American Depositary Shares (93,333 underlying)
Footnotes (5)
- [F1]Each American Depositary Share ("ADS") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer.
- [F2]Ms. Hughes-Wilson sold a total of 100,432 ADSs solely to pay a tax obligation, and all proceeds are being used for such taxes.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $2.88 to $3.04, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges
- [F4]160,000 options were issued on 01/14/2022 and 25% of the shares underlying this award became exercisable on January 14, 2023, with the remainder vesting in equal monthly installments thereafter.
- [F5]240,000 options were issued on 01/25/2023 and 25% of the shares underlying this award became exercisable on January 25, 2024, with the remainder vesting in equal monthly installments thereafter.
Documents
Issuer
Mereo BioPharma Group plc
CIK 0001719714
Entity typeother
Related Parties
1- filerCIK 0002005875
Filing Metadata
- Form type
- 4
- Filed
- May 22, 8:00 PM ET
- Accepted
- May 23, 9:54 PM ET
- Size
- 17.8 KB